USSTOCK.TODAY
Market Closed Log in Sign up

Theravance Biopharma Inc(TBPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

Halted
Trading Halted Since 2026-10-19: Trading has been halted. It may resume, and prices shown reflect the last trading day.
TBPH
TBPH
Halted
Theravance Biopharma Inc
At close Sep 23 at 4:00 PM ET (Korea 9/24 05:00)
$17.03
+0.00 +0.00%
Symmetrical Triangle Resistance 16.95 Support 17.13 Ended Same lines for 4 days

AI-drawn chart patterns are for reference only.

Full metrics table

Index ⓘ -P/E ⓘ 16.87EPS (ttm) ⓘ 1.01Insider Own ⓘ -Shs Outstand ⓘ 51.9MPerf Week ⓘ -
Market Cap ⓘ 0.88BForward P/E ⓘ 9.73EPS next Y ⓘ -37.5%Insider Trans ⓘ -Shs Float ⓘ 48.7MPerf Month ⓘ 0.06%
Enterprise Value ⓘ 0.57BPEG ⓘ -EPS next Q ⓘ 0.32Inst Own ⓘ 79.38%Short Float ⓘ 3.46%Perf Quarter ⓘ 0.77%
Income ⓘ 0.05BP/S ⓘ 8.47EPS this Y ⓘ 35.92%Inst Trans ⓘ -Short Ratio ⓘ 1.95Perf Half Y ⓘ 4.16%
Sales ⓘ 0.10BP/B ⓘ 3.05EPS next 5Y ⓘ -9.64%ROA ⓘ 12.01%Short Interest ⓘ 1.69MPerf YTD ⓘ -8.98%
Book/sh ⓘ 5.58P/C ⓘ 2.28EPS past 3/5Y ⓘ -ROE ⓘ 20.91%52W High ⓘ -19.02% ($21.03)Perf Year ⓘ 21.04%
Cash/sh ⓘ 7.47P/FCF ⓘ 16.45Sales past 3/5Y ⓘ 27.91% 8.38%ROIC ⓘ 15.36%52W Low ⓘ 30.2% ($13.08)Perf 3Y ⓘ 86.94%
Dividend Est. ⓘ -EV/EBITDA ⓘ 70.92EPS Y/Y TTM ⓘ 331.61%Gross Margin ⓘ 94.45%Volatility(W/M) ⓘ 0.22% 0.3%Perf 5Y ⓘ 140.2%
Dividend TTM ⓘ -EV/Sales ⓘ 5.44Sales Y/Y TTM ⓘ 35.11%Oper. Margin ⓘ 2.12%ATR (14) ⓘ 0.06Perf 10Y ⓘ -52.42%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 13.54EPS Q/Q ⓘ -110.56%Profit Margin ⓘ 51.58%RSI (14) ⓘ 53.28Recom ⓘ 3
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 13.54Sales Q/Q ⓘ -20.86%SMA20 ⓘ -0.07% ($17.04)Beta ⓘ 0.18Target Price ⓘ $17
Payout ⓘ -Debt/Eq ⓘ 0.25Earnings ⓘ 2026/8/10SMA50 ⓘ 0.39% ($16.96)Rel Volume ⓘ 0Prev Close ⓘ $17.03
Employees ⓘ 90LT Debt/Eq ⓘ 0.21EPS/Sales Surpr. ⓘ -251.72% -7.84%SMA200 ⓘ -0.87% ($17.18)Avg Volume(3M) ⓘ 0.87MPrice ⓘ $17.03
IPO ⓘ 2014/5/16Option/Short ⓘ Yes/NoTrades ⓘ 0Volume ⓘ -Change ⓘ -
Company
TBPH TBPHTheravance Biopharma Inc | NASD | Biotechnology Deep dive

Theravance Biopharma is a biotech company built around respiratory therapeutic assets. It shares the U.S. commercialization revenue from its lead asset, YUPELRI (revefenacin) inhalation solution, with its partner, while also collecting revenue from royalties on partner assets such as the legacy TRELEGY royalty. The ticker is TBPH. Recently, the company has significantly scaled back its in-house drug development and restructured its business around a royalty and revenue collection model.

Quote

Over the past 1 year, roughly in the middle

19% below its 1-year high.

Now $17.03
52w low$13.0852w high$21.03
52W Range50%
Volume ⓘ 0

Traded less than usual. That is 0% of its average volume.

B
Overall · fairly good
We judged 7 of the 8 questions below. 3 rate excellent and 1 need caution.
Not applicable: dividends.
ETFs holding this stock 5 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #157 of 599 in the industry

Based on market cap of $884M.

FAQ

FAQ

TBPH belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of TBPH is approximately $884M, ranking 2,693 within its sector.

TBPH has a P/E ratio of approximately 16.9x, which can be used to assess its valuation relative to the Healthcare sector average.

TBPH has recorded a 52-week high of $21.03 and a low of $13.08.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels